期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 135, 期 3, 页码 737-U248出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2014.11.034
关键词
Peanut allergy; oral immunotherapy; probiotic; immune-modifying adjuvant; tolerance; sustained unresponsiveness; desensitization; peanut-specific IgE; peanut-specific IgG(4)
资金
- Food Allergy and Anaphylaxis Network (FAAN)
- Murdoch Childrens Research Institute, Perpetual Philanthropy [493]
- CASS Foundation
- Financial Markets Foundation for Children
- National Health and Medical Research Council Australia (NHMRC) [1029690]
Background: Coadministration of a bacterial adjuvant with oral immunotherapy (OIT) has been suggested as a potential treatment for food allergy. Objective: To evaluate a combined therapy comprising a probiotic together with peanut OIT. Methods: We performed a double-blind, placebo-controlled randomized trial of the probiotic Lactobacillus rhamnosus CGMCC 1.3724 and peanut OIT (probiotic and peanut oral immunotherapy [PPOIT]) in children (1-10 years) with peanut allergy. The primary outcome was induction of sustained unresponsiveness 2 to 5 weeks after discontinuation of treatment (referred to as possible sustained unresponsiveness). Secondary outcomes were desensitization, peanut skin prick test, and specific IgE and specific IgG4 measurements. Results: Sixty-two children were randomized and stratified by age (<= 5 and > 5 years) and peanut skin test wheal size (<= 10 and > 10 mm); 56 reached the trial's end. Baseline demographics were similar across groups. Possible sustained unresponsiveness was achieved in 82.1% receiving PPOIT and 3.6% receiving placebo (P<. 001). Nine children need to be treated for 7 to achieve sustained unresponsiveness (number needed to treat, 1.27; 95% CI, 1.06-1.59). Of the subjects, 89.7% receiving PPOIT and 7.1% receiving placebo were desensitized (P <.001). PPOIT was associated with reduced peanut skin prick test responses and peanut-specific IgE levels and increased peanut-specific IgG4 levels (all P <.001). PPOIT-treated participants reported a greater number of adverse events, mostly with maintenance home dosing. Conclusion: This is the first randomized placebo-controlled trial evaluating the novel coadministration of a probiotic and peanut OIT and assessing sustained unresponsiveness in children with peanut allergy. PPOIT was effective in inducing possible sustained unresponsiveness and immune changes that suggest modulation of the peanut-specific immune response. Further work is required to confirm sustained unresponsiveness after a longer period of secondary peanut elimination and to clarify the relative contributions of probiotics versus OIT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据